- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03472794
Adaptation of a Knowledges Exchange Portal Between (KEP) Healers and Patients : Obstacles and Sources to KEP Use for Breast Cancer Women (Sav-AQ)
Adaptation of a Knowledges Exchange Portal (KEP) Between Healers and Patients : Study of Obstacles and Sources to the Use of a KEP in the Case of Women Affected by a Breast Cancer in Nouvelle Aquitaine(Sav-AQ)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
One of the French Cancer Plan 2014-2019 objectives is to improve the town-hospital coordination and information's exchange between professionals. This research project aims to reach this important objective of exchange development and the amelioration of the coordination concerning breast cancer women. Breast cancer requires the integration of aggressive treatments implying physical, psychological and social consequences. That's why an optimized care pathway needs a coordinated and multidisciplinary organization, and more particularly a personalized approach taking into account the whole patients' needs in physical, psychological and social perspectives. To reach this goal, it is important to support those patients, to answer their needs for a better disease management in their own health pathways. The research issues lie in this outcome.
The project is imbued with the whole problematic of patient follow-up and patient support, taking into account the experiences and needs of breast cancer patients. It concerns the dissemination of knowledge through the implementation of a specific clinical innovation designed to optimizing breast cancer patient pathway.
The " Patients en réseau " association offers us to participate at the web platform evolution Mon Réseau Cancer du Sein in adapting it. The feasibility study focuses on (1) the platform utilization and (2) sources and obstacles to its utilization in the French context
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33000
- Institut Bergonie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
30 women with a breast cancer will participate to the study, they will represent a sufficient and realis effective considering the active list of treated patients with a breast cancer at the Bergonié Institute.
5 healers (one nurse, two doctors, a senior health manager, a manipulator in medical imaging)
Description
Inclusion criteria of patients :
- Age ≥ 18 y.o;
- With a diagnosis of breast cancer,
- treated at the Bergonié Institute;
- Patients who express a non-opposition to participate to SAVAQ research;
- Patients who have an Internet access at home.
Inclusion criteria of healers :
- Doctors, Nurse, Senior health manager, Technologist medical imaging from the center participated to the research
Exclusion criteria of patients:
- Patients with a severe psychiatric pathology (medical diagnosis);
- Patients who doesn't speak French
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasability of the web portal
Time Frame: Month 6
|
Number of connections to the portal each month:
|
Month 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of the portal connections realized each month
Time Frame: Month 6
|
Number of the portal connections realized each month
|
Month 6
|
Number of webpages used
Time Frame: Month 6
|
Number of webpages used
|
Month 6
|
Number of status posted
Time Frame: Month 6
|
Number of status posted
|
Month 6
|
Number of comments/questions posted
Time Frame: Month 6
|
Number of comments/questions posted
|
Month 6
|
Number of "like" emoticon posted
Time Frame: Month 6
|
Number of "like" emoticon posted
|
Month 6
|
Number of "comfort" emoticon posted
Time Frame: Month 6
|
Number of "comfort" emoticon posted
|
Month 6
|
Number of "favorites" emoticon posted
Time Frame: Month 6
|
Number of "favorites" emoticon posted
|
Month 6
|
Number of "mood" posted
Time Frame: Month 6
|
Number of "mood" posted
|
Month 6
|
Number of private posts posted
Time Frame: Month 6
|
Number of private posts posted
|
Month 6
|
Number of webpages consulted
Time Frame: Month 6
|
Number of webpages consulted
|
Month 6
|
Number of leaflets consulted
Time Frame: Month 6
|
Number of leaflets consulted
|
Month 6
|
Headings of leaflets consulted
Time Frame: Month 6
|
Headings of leaflets consulted
|
Month 6
|
Number of cards consulted
Time Frame: Month 6
|
Number of cards consulted
|
Month 6
|
Headings of cards consulted
Time Frame: Month 6
|
Headings of cards consulted
|
Month 6
|
Number of videos consulted
Time Frame: Month 6
|
Number of videos consulted
|
Month 6
|
Headings of videos consulted
Time Frame: Month 6
|
Headings of videos consulted
|
Month 6
|
Number of address consulted in the address list
Time Frame: Month 6
|
Number of address consulted in the address list
|
Month 6
|
Number of upcoming events consulted
Time Frame: Month 6
|
Number of upcoming events consulted
|
Month 6
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2016/19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer